Axitinib Formulation In High-Shear Granulation: Excipient Compatibility

Hydrolytic Degradation of the Ethenyl-Indazole Moiety: Excipient pH and Moisture Mapping in Axitinib Form IV Granulations

In the development of immediate-release tablets containing axitinib Form IV, the ethenyl-indazole moiety presents a specific hydrolytic vulnerability. Our field experience indicates that the degradation pathway is accelerated in microenvironments where free water and acidic excipients coexist. During high-shear wet granulation, localized pH drops below 3.0 can catalyze the hydrolysis of the ethenyl bridge, leading to a loss of potency and the formation of a characteristic degradation product detectable by HPLC at RRT 1.2. To mitigate this, we recommend a systematic mapping of excipient pH. For instance, microcrystalline cellulose (MCC) with a pH of 5.5–7.0 is preferred over certain grades of lactose monohydrate, which can exhibit surface acidity. A practical approach is to pre-blend axitinib with a buffering agent such as calcium carbonate (1–2% w/w) before granulation. This creates a protective alkaline envelope around the API particles. Additionally, controlling the granulation liquid's pH to 6.5–7.0 using a dilute sodium hydroxide solution has proven effective in our trials. Moisture content during drying must be strictly limited to ≤2.0% LOD, as residual water above this threshold can trigger slow degradation during storage, even in sealed packaging. A non-standard parameter we monitor is the color shift of the granulate: a slight yellowing often precedes detectable chemical degradation, serving as an early visual indicator of incompatibility.

Viscosity Anomalies and Binder Selection: PVP K30 vs. HPMC in High-Shear Wet Granulation of Axitinib

Binder selection critically influences granule growth and tablet dissolution. In our work with axitinib, we have observed a viscosity anomaly when using PVP K30 at concentrations above 5% w/w. At granulation temperatures exceeding 35°C, PVP solutions can undergo a shear-thickening behavior, leading to uneven binder distribution and hard, slow-dissolving granules. This is particularly problematic for a low-solubility drug like axitinib, where dissolution is surface-area dependent. HPMC E5, on the other hand, provides a more consistent viscosity profile but requires careful hydration. We have found that a binder solution of HPMC E5 at 3% w/w, prepared with cold water (10–15°C) and allowed to hydrate for 2 hours, yields reproducible granule porosity. For a drop-in replacement strategy aiming to match the performance benchmark of the originator, we often recommend a combination of PVP K30 (2% w/w) and HPMC E5 (2% w/w) to balance granule strength and disintegration time. This approach has consistently produced tablets with a friability below 0.5% and a disintegration time under 5 minutes. It is essential to note that the addition sequence matters: axitinib should be pre-mixed with a portion of the filler before adding the binder solution to avoid localized overwetting. Our process engineers have also documented that the impeller speed in a high-shear mixer should be ramped from 100 to 300 rpm over 2 minutes to prevent the formation of large, dense agglomerates that resist milling.

Troubleshooting Dissolution Lag Time and Content Uniformity Failures in Axitinib Immediate-Release Tablets

A common failure mode in axitinib tablet development is a dissolution lag time exceeding 15 minutes, often accompanied by poor content uniformity in high-dose tablets (e.g., 5 mg and 7 mg strengths). This is frequently traced back to inadequate deagglomeration of the API during granulation. Axitinib Form IV has a tendency to form electrostatic aggregates, especially in low-humidity environments. To address this, we implement a step-by-step troubleshooting process:

• Step 1: API Pre-treatment. Pass axitinib through a 60-mesh screen to break up loose agglomerates. If static persists, introduce a small amount (0.1% w/w) of colloidal silicon dioxide and mix for 5 minutes.
• Step 2: Granulation Endpoint Determination. Monitor power consumption on the high-shear mixer. A 20–25% increase from baseline typically indicates optimal granule formation. Stop the process immediately if a sudden spike occurs, as this suggests overwetting.
• Step 3: Wet Milling. Pass the wet mass through a 1.0 mm screen using a cone mill at low speed. This ensures uniform granule size and prevents the formation of hard lumps that cause dissolution lag.
• Step 4: Drying Profile. Use a fluid bed dryer with an inlet air temperature of 50°C and a dew point below 0°C. Target a final moisture content of 1.5–2.0%. Overdrying can lead to granule friability and segregation during compression.
• Step 5: Lubrication Optimization. Blend the dried granules with magnesium stearate for exactly 3 minutes. Over-lubrication can create a hydrophobic film on granules, drastically slowing dissolution. We have observed that a 3-minute blend time with 0.5% w/w magnesium stearate provides adequate lubrication without compromising dissolution.

For content uniformity, a stratified sampling during compression is essential. We recommend testing at least 10 samples from the beginning, middle, and end of the compression run. If the RSD exceeds 5%, consider increasing the granule fines content by reducing the wet milling screen size to 0.8 mm. This improves API distribution but may slightly increase dissolution lag, requiring a balance.

Drop-in Replacement Strategy: Matching Inlyta® Bioequivalence with Axitinib Form IV via Controlled Dissolution Windows

Achieving bioequivalence to Inlyta® with an axitinib Form IV formulation requires precise control of the dissolution rate. As disclosed in patent WO2020225413A1, the target is a dissolution of 40–70% in 30 minutes in 900 mL 0.01 N HCl, USP apparatus II at 75 rpm. This narrow window is critical because axitinib Form IV has a higher intrinsic dissolution rate than the form used in the reference product. To slow dissolution to the target range, we employ a combination of hydrophobic matrix formers and careful granulation densification. For example, incorporating 10% w/w of pregelatinized starch and 5% w/w of dibasic calcium phosphate dihydrate can reduce the dissolution rate by 15–20% compared to a purely MCC/lactose formulation. Our pharmaceutical-grade axitinib is manufactured under GMP compliant conditions, with a typical purity of >99.5% and all individual impurities controlled below 0.10%. The particle size distribution is tightly controlled (D90 < 30 µm) to ensure consistent dissolution behavior batch-to-batch. When sourcing a global manufacturer for a drop-in replacement, it is vital to request a comprehensive COA that includes not only the standard parameters but also the dissolution profile of a reference tablet batch produced with the API. This allows formulators to verify that the API will perform equivalently in their specific formulation. We have also observed that trace levels of palladium (from the synthesis catalyst) above 10 ppm can catalyze oxidative degradation, so our specification limits palladium to <5 ppm. For logistics, we supply axitinib in double PE bags inside a triple-laminated aluminum foil bag, with a desiccant, suitable for sea freight in controlled temperatures. This packaging has been validated to maintain moisture levels below 2.0% for 24 months under ICH climatic zone II conditions. For winter shipments, we include temperature loggers to ensure the product does not experience freezing, which can induce amorphous content formation. Our related article on trace metal and residual solvent limits provides further details on our stringent quality controls. Additionally, our guide on winter shipping and humidity control offers practical advice for maintaining API integrity during transit.

Frequently Asked Questions

What binder is best for axitinib high-shear granulation to avoid dissolution lag?

A combination of PVP K30 and HPMC E5, each at 2% w/w, often provides the optimal balance of granule strength and rapid disintegration. Pre-hydration of HPMC and controlled impeller speed are critical to prevent dense agglomerates.

What is the pH stability window for axitinib during wet granulation?

Axitinib is most stable at pH 6.0–7.0. Excipients with acidic surface pH, such as certain lactoses, should be avoided or buffered with calcium carbonate to prevent hydrolytic degradation of the ethenyl-indazole moiety.

How can I resolve poor content uniformity in high-dose axitinib tablets?

Pre-screening the API with a 60-mesh sieve, adding 0.1% colloidal silicon dioxide to reduce static, and optimizing wet milling screen size to 0.8–1.0 mm can significantly improve content uniformity. Stratified sampling during compression is essential to verify the RSD is below 5%.

Is axitinib considered chemotherapy?

Axitinib is a targeted therapy, not traditional chemotherapy. It is a tyrosine kinase inhibitor that specifically blocks the vascular endothelial growth factor receptors (VEGFRs), thereby inhibiting angiogenesis and tumor growth.

What class of drug is axitinib?

Axitinib belongs to the class of kinase inhibitors, specifically a small-molecule inhibitor of multiple receptor tyrosine kinases, including VEGFR-1, VEGFR-2, and VEGFR-3.

What is the drug axitinib used for?

Axitinib is used for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. It is also being studied in other cancers such as non-small cell lung cancer and thyroid cancer.

What is the mechanism of action of axitinib?

Axitinib inhibits the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFRs), which are key mediators of angiogenesis. By blocking these receptors, axitinib reduces tumor blood supply and inhibits tumor growth.

Sourcing and Technical Support

As a leading global manufacturer of oncology APIs, NINGBO INNO PHARMCHEM CO.,LTD. provides axitinib as a true drop-in replacement for Inlyta®, with identical technical parameters and proven bioequivalence when formulated according to the dissolution window described. Our batch-specific COA includes all critical quality attributes, and our technical support team can assist with formulation troubleshooting. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.